{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:00:43Z","timestamp":1790740843080,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202108440215"],"award-info":[{"award-number":["202108440215"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bone.2026.118085","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:57:45Z","timestamp":1788796665000},"page":"118085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effectiveness and limitations of anti-sclerostin therapy in osteogenesis imperfecta: A systematic review"],"prefix":"10.1016","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9764-2901","authenticated-orcid":false,"given":"Zhiming","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9797-1939","authenticated-orcid":false,"given":"Suzanne","family":"den Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4855-4891","authenticated-orcid":false,"given":"Faith","family":"Perek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6683-7549","authenticated-orcid":false,"given":"Wouter","family":"Nijhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2275-6170","authenticated-orcid":false,"given":"Harrie","family":"Weinans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-9314","authenticated-orcid":false,"given":"Ralph","family":"Sakkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4959-4562","authenticated-orcid":false,"given":"Anne","family":"Spaans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4131-675X","authenticated-orcid":false,"given":"Kelly","family":"Warmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2026.118085_bb0005","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2026.118085_bb0010","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2026.118085_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1302\/1863-2548.13.180190","article-title":"Current concepts in osteogenesis imperfecta: bone structure, biomechanics and medical management","volume":"13","author":"Nijhuis","year":"2019","journal-title":"J. Child. Orthop."},{"key":"10.1016\/j.bone.2026.118085_bb0020","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.bone.2026.118085_bb0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18388\/abp.2002_3802","article-title":"Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans","volume":"49","author":"Gajko-Galicka","year":"2002","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.bone.2026.118085_bb0030","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2026.118085_bb0035","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1210\/jc.2005-2413","article-title":"Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation","volume":"91","author":"Rauch","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.118085_bb0040","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2026.118085_bb0045","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2026.118085_bb0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0055","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.bone.2026.118085_bb0060","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2026.118085_bb0070","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118085_bb0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0080","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-20-0299","article-title":"Osteogenesis imperfecta: an update on clinical features and therapies","volume":"183","author":"Marom","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2026.118085_bb0085","first-page":"39","article-title":"Sclerostin inhibition in rare bone diseases: molecular understanding and therapeutic perspectives","volume":"47","author":"Xiaohui","year":"2024","journal-title":"J. Orthop. Transl."},{"key":"10.1016\/j.bone.2026.118085_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10377","article-title":"Gene expression profile and acute gene expression response to sclerostin inhibition in osteogenesis imperfecta bone","volume":"4","author":"Surowiec","year":"2020","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2026.118085_bb0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","article-title":"Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta","volume":"124","author":"Cardinal","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118085_bb0100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00223-019-00655-5","article-title":"Sclerostin-antibody treatment decreases fracture rates in axial skeleton and improves the skeletal phenotype in growing oim\/oim mice","volume":"106","author":"Cardinal","year":"2020","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2026.118085_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.705505","article-title":"Gender-related impact of sclerostin antibody on bone in the osteogenesis imperfecta mouse","volume":"12","author":"Cardinal","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.bone.2026.118085_bb0110","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.118085_bb0115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2016.01.001","article-title":"Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age","volume":"84","author":"Sinder","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118085_bb0120","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1172\/JCI92617","article-title":"Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis","volume":"127","author":"Joeng","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2026.118085_bb0125","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1038\/s41598-023-32221-3","article-title":"Effect of sclerostin inactivation in a mouse model of severe dominant osteogenesis imperfecta","volume":"13","author":"Marulanda","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2026.118085_bb0130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118085_bb0135","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.7150\/thno.63177","article-title":"Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bone.2026.118085_bb0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbrc.2018.12.111","article-title":"Endoplasmic reticulum stress is induced in growth plate hypertrophic chondrocytes in G610C mouse model of osteogenesis imperfecta","volume":"509","author":"Scheiber","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2026.118085_bb0145","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap\u2212\/\u2212 mice, a model of recessive Osteogenesis Imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0150","series-title":"Photonic Therapeutics and Diagnostics XI","first-page":"400","article-title":"Tissue level material composition and mechanical properties in Brtl\/+ mouse model of Osteogenesis Imperfecta after sclerostin antibody treatment","author":"Lloyd","year":"2015"},{"key":"10.1016\/j.bone.2026.118085_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117167","article-title":"Sclerostin antibody enhances implant osseointegration in bone with Col1a1 mutation","volume":"186","author":"Sung","year":"2024","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118085_bb0160","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0165","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","article-title":"Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study","volume":"39","author":"Glorieux","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0170","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/jbmr\/zjae108","article-title":"Bone matrix properties in adults with osteogenesis imperfecta are not adversely affected by setrusumab-a sclerostin neutralizing antibody","volume":"39","author":"Rummler","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0175","doi-asserted-by":"crossref","first-page":"494","DOI":"10.11124\/JBIES-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid. Synth."},{"key":"10.1016\/j.bone.2026.118085_bb0180","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap(\u2212\/\u2212) mice, a model of recessive osteogenesis imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0185","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/jbmr.3858","article-title":"Sclerostin antibody-induced changes in bone mass are site specific in developing crania","volume":"34","author":"Scheiber","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0190","article-title":"Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation","volume":"13","author":"Yu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bone.2026.118085_bb0195","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2026.118085_bb0200","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0205","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0215","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0220","doi-asserted-by":"crossref","first-page":"9290","DOI":"10.1016\/j.biomaterials.2014.07.051","article-title":"The influence of age on adaptive bone formation and bone resorption","volume":"35","author":"Birkhold","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.bone.2026.118085_bb0225","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bone.2026.118085_bb0230","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jbmr.3038","article-title":"Sclerostin antibody administration converts bone lining cells into active osteoblasts","volume":"32","author":"Kim","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0235","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118085_bb0240","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2011.10.025","article-title":"Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading","volume":"50","author":"Tu","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118085_bb0245","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bone.2016.10.008","article-title":"Sclerostin's role in bone's adaptive response to mechanical loading","volume":"96","author":"Galea","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118085_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0040007","article-title":"ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta","volume":"4","author":"Lisse","year":"2008","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bone.2026.118085_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10674","article-title":"Accelerated aging in cyclophilin B-deficient mice downstream of p21-Cip1\/Waf1","volume":"6","author":"Zhang","year":"2022","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2026.118085_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166741","article-title":"Deep intronic mutation in CRTAP results in unstable isoforms of the protein to induce type I collagen aggregation in a lethal type of osteogenesis imperfecta type VII","volume":"1869","author":"Udupa","year":"2023","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.bone.2026.118085_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102073","article-title":"A bimolecular modification strategy for developing long-lasting bone anabolic aptamer","volume":"34","author":"Zhang","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bone.2026.118085_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102146","article-title":"Unique quinoline orientations shape the modified aptamer to sclerostin for enhanced binding affinity and bone anabolic potential","volume":"35","author":"Gubu","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bone.2026.118085_bb0275","doi-asserted-by":"crossref","first-page":"18883","DOI":"10.1021\/acs.jmedchem.4c01293","article-title":"Developing stapled aptamers with a constrained conformation for osteogenesis imperfect therapeutics","volume":"67","author":"Amu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bone.2026.118085_bb0280","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1021\/jacsau.5c00827","article-title":"Harnessing bone-liver crosstalk: a dual-action LYTAC approach for bone-specific accumulation and liver-specific protein degradation in bone disorders","volume":"5","author":"Ma","year":"2025","journal-title":"JACS Au"},{"key":"10.1016\/j.bone.2026.118085_bb0285","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2017.04.016","article-title":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta","volume":"101","author":"Little","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118085_bb0290","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2026.118085_bb0295","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822600311X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822600311X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:36:04Z","timestamp":1790739364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632822600311X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":59,"alternative-id":["S875632822600311X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.118085","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and limitations of anti-sclerostin therapy in osteogenesis imperfecta: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.118085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118085"}}